

AI, FHIR, EHDS & the AI Act: Impacts on Healthcare Software and Standards

Stefano Micocci

Fondazione Bruno Kessler Italy affiliated to HL7 Italy member of HL7 Italy directive board

Introduce myself



CTO of Strategic Planning Office
Fondazione Bruno Kessler (FBK) - Trento
Secretary of HL7 Italy & Digital Health Expert



Involved in strategic planning of digital health ecosystems that bridge research and public health implementation. (FBK)

- National Strategy: he was scientific consultant for the Italian Digital Transformation Department on the "Fascicolo Sanitario Elettronico" (FSE 2.0). Now scientific consultant of Autonomous Province of Trento
- Standards Leadership: Active in HL7 Europe Working Groups, focusing on AI certification and EHDS interoperability.
- Innovation: Leads projects on AI as Software as a Medical Device (SaMD) and citizen-centric digital health platforms.

Agenda



- Objective of this meeting
- Standard and AI development: European context
- HL7 community: challenges and contributions
- Round table: our feedback, interests and expertise
- Next step: what we can do together

Objective of this meeting





Assess the interest on the topic "relationship between AI and application of standard" and learn about our expertise



Discuss How FHIR can support EHDS & the AI Act compliance for secondary use of the data



Identify actions and topics that could be addressed by HL7 community next year



Standard and AI development: European context

Standard HL7 and AI Development: The European Context



The "Dual-Compliance" Challenge




What is the possible role of the standardization bodies? What is the role of HL7?

The European healthcare landscape is changing because of the introduction of AI

The convergence of the **EU AI Act** and the **European Health Data Space** (**EHDS**) creates a complex regulatory environment.

AI in Clinical Practice: Process Transformation





Diagnostic Triage

Al algorithms pre-screen and flag critical radiological findings before human review.


CHANGE: SHIFT FROM FIFO QUEUES TO RISK-PRIORITIZED WORKFLOW.



Predictive Monitoring

Real-time analysis of vital signs to predict adverse events like sepsis hours in advance.

CHANGE: SHIFT FROM REACTIVE TREATMENT TO PROACTIVE PREVENTION.



Precision Medicine


Correlating vast genomic datasets with clinical outcomes to identify optimal therapies.

CHANGE: SHIFT FROM TRIAL-AND-ERROR TO TARGETED PRECISION DOSING.

What is the possible role of standardization body?



- Leveraging EHDS Secondary Use mandates to transform isolated clinical data into high-value AI training assets.
- Semantic Interoperability for RWD: Utilizing FHIR as anormalization layer to convert heterogeneous Real-World Data(RWD) into standardized datasets (e.g., mapping FHIR to OMOPCDM) for robust model training.
- Anonymization Pipelines: Implementing standard-based deidentification profiles to ensure GDPR compliance while retaining longitudinal clinical value for research cohorts.
- Reproducible AI: Standardizing "Metadata" and "Provenance" resources to document data lineage, ensuring that AI research models are transparent and reproducible across EU borders.



Optimizing AI Data Lifecycle with FHIR



Curation & Labeling

Quality Assurance: Using Provenance to track data lineage and QuestionnaireResponse for structured ground-truth labeling and validation.

Deployment Loop

Continuous Learning: Capturing model inference via RiskAssessment and clinical outcomes for drift detection and retraining.

Data Acquisition

Standardized Ingestion: FHIR

APIs enable unified data extraction (e.g., Patient,

Observation) from heterogeneous

EHRs, reducing preparation time.

Model Training

Cohort Definition: Utilizing Group resources to define precise training populations and Consent resources to manage data usage rights.

Strategic Imperatives for Decision Makers





Harmonized Compliance

Aligning vertical AI Act safety controls with horizontal MyHealth@EU data flows. This harmonization reduces regulatory friction and prevents the need for separate compliance silos.



Trust Architecture

Leveraging open HL7 standards to build explainable, transparent Al systems. Standardized data provenance acts as a trust signal for clinicians and patients across borders.



Cross-Border Scale

Preparing infrastructure for the EHDS.

Adopting Al-ready standards today
ensures seamless, secure health data
exchange across EU member states
tomorrow.



Focus on euopean regulation

Why AI Act & EHDS Matter for Healthcare AI





European Health Data Space (EHDS)

Focuses on health data governance (primary and secondary use). Defines how we access data.



AI Act

systems used in healthcare are almost always classified as high-risk, triggering strict requirements on data managment, transparency, human oversight and data management.



Technical Standards

Provide "operational translations" of legal requirements, and are expected to be used as evidence of compliance ("presumption of conformity")

Al Act: High-Risk Healthcare Al and Data Governance



Regulates the development, placing on the market, and use of AI systems in the EU, with a risk-based approach; most clinical AI falls under "high-risk" systems (e.g. AI-enabled medical devices).

Many of these obligations explicitly rely on detailed technical standards and structured documentation – an area where HL7 FHIR-based models for Al transparency, provenance and data lifecycle can provide concrete implementation artefacts.

Key lifecycle obligations for high-risk systems (selected):

- Art. 9 Continuous risk management system across the whole lifecycle.
- Art. 10 Data & data governance: training/validation/test datasets must be relevant, representative, free of errors and complete, with documented governance and management practices.
- Art. 11–12 Technical documentation and logging to ensure traceability and post-hoc analysis.
- Art. 13–15 Transparency, human oversight, accuracy, robustness and cybersecurity with declared performance metrics.
- Art. 16–17, 72–73 Quality management system, CE conformity assessment, and post-market monitoring/incident reporting.

European Health Data Space (EHDS) main principles



EHDS regulates **access and use of electronic health data**, creating a legal and technical framework for both primary (care) and secondary use (research & innovation, including Al development).

- Allowed: for secondary use, EHDS explicitly includes "development, training, testing and validation of AI algorithms" aimed at improving public health and healthcare quality;
- Denied: uses such as marketing or discriminatory insurance pricing are excluded.

Access occurs only inside secure processing environments:

- Data are anonymous or pseudonymous by default;
- Raw source data never leave the environment;
- Only non-identifying aggregate outputs or trained models can be exported;
- All operations are logged for accountability.
- Data access is mediated by national Health Data Access Bodies, which issue time-bound data permits specifying which data can be used, for which purpose, and under which conditions.



HL7 community: challenges and contributions





Key Objectives:

- Standardization: Creating frameworks for safe, transparent, and interoperable AI.
- Global Forum: gather technology experts, clinicians,
 and regulators to shape the future of Al in healthcare
- Responsible Innovation: Ensuring ethical AI that improves patient outcomes.

Operational Pillars:

- Al Innovation Lab: An incubator for accelerating standards.
- Community Excellence: Tools for responsible adoption.





HL7 international AI Office: A Strategic umbrella launched in July 2025

Key Objectives

- **Standardization:** Creating frameworks for safe, transparent, and interoperable AI.
- Global Forum: gather technology experts, clinicians, and regulators to shape the future of AI in healthcare
- Responsible Innovation: ensuring ethical AI that improves patient outcomes.

Operational Pillars

- Al Innovation Lab: An incubator for accelerating standards.
- Community Excellence: Tools for responsible adoption.



HL7 international focus group— Artificial Intelligence



Activitities

- HL7 EHR Work Group/Artificial Intelligence Focus Team
- Informative Document on data used foro machine learning models (August 2024)

Reference:

Gary Dickinson

HL7 EHR Work Group - Artificial Intelligence Focus Team - Confluence Page

Data life cycle for Machine Learning models



AI/ML Data Lifecycle Edition 1 – US Realm

August 2024

HL7 Informative Document
Phase I: Data Used for
Machine Learning Models

Sponsored by: HL7 Electronic Health Records (EHR) Work Group

Gary Dickinson FHL7	Mark Janczewski MD MPH
Co-Chair, HL7 EHR Work Group	Co-Chair, HL7 EHR Work Group
EHR Standards Consulting	Medical Networks, LLC
Michael Brody DPM	John Ritter FHL7
Co-Chair, HI7 EHR Work Group	Co-Chair, HL7 EHR Work Group
Registry Clearinghouse	
Pele Yu MD	Michael van der Zel
Co-Chair, H7 EHR Work Group	Co-Chair, HI7 EHR Work Group
University of Arkansas Medical	HL7 Netherlands
Sciences	
	Lincoln Weed JD
	Co-Chair, HL7 EHR Work Group

Copyright © 2024 Health Level Seven International * ALL RIGHTS RESERVED. The reproduction of this material in any form is strictly forbidden without the written permission of the publisher. HL7 and Health Level Seven are registered trademarks of Health Level Seven International Rep LLS P. B. T.M.Off.

Use of this material is governed by HL7's IP Compliance Policy

HL7 Europe: areas of possible interest



- Interoperability of AI System: support standard extension and new profiles that allow AI models trained on standardized data to be deployed in different organizations without retraining.
- **Federated Learning /validation:** it is feasible when FHIR standards ensure data consistency (it mitigates privacy concerns in data training). Without this alignment, the aggregation of results becomes heterogeneous and unreliable. This issue is particularly relevant when datasets reside in different Countries.
- **Regulatory Compliance:** how standards can support compliance with emerging EU AI regulations, with a focus on Transparency and eXplainable AI (XAI)
- Data enrichment for secondary use (data lifecycle support): how FHIR can support the data preparation pipeline from real world data to AI-ready data



Round table: our feedback, interests and expertise

Open discussion

Sharing experience – some contributions



- Flavio Ragni, researcher and data scientist, Fondazione Bruno Kessler Italy
- Ignacio Jauregui, Senior Interoperability Standardization Manager, Philips –
 Netherlands
- Roberta Gazzarata, member of HL7 Italy directive, leader WG <u>Cancer</u>
 <u>Common Model</u>
- Stefano Lotti, President of HL7 Italy

Next step



- Collect our contacts, expertise
- List working group we are involved in: which implementation guide is relevant addressing these aspects? Which ones?
- Something else?

WGM HL7 Europe Cologne AI FHIR EHDS and AI Act folder



Thanks

smicocci@fbk.eu

https://www.fbk.eu/en/

https://www.hl7.it